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ABSTRACT
Introduction: Many children with juvenile idiopathic
arthritis ( JIA) continue to have active disease into
adulthood. Adults with JIA are a heterogeneous group,
and the effects of tumour necrosis factor inhibitor
(TNFi) therapies are not well described. This analysis
aims to describe treatment outcomes among patients
with JIA starting TNFi for the first time in adulthood.
Methods: Patients with arthritis onset <16 years
starting their first TNFi therapy were identified from the
British Society of Rheumatology Biologics Register.
Disease activity outcomes (using 28-joint Disease
Activity Score (DAS28) and Health Assessment
Questionnaire (HAQ)) are presented at 1 year after start
of therapy according to disease pattern. Incidence rates
(IR) of adverse events per 1000 person-years (pyrs)
were calculated. Outcomes in patients with
polyarticular JIA were compared with a cohort
(weighted for age and gender) of patients with
rheumatoid arthritis (RA).
Results: In 443 adults with JIA starting a first TNFi,
disease activity over 1 year improved across all
measures. There were 58 first serious infections
(IR 22.3/1000 pyrs); 4 cardiovascular events
(IR 1.4/1000 pyrs); 11 uveitis events (IR 4.0/1000
pyrs) and 16 malignancies (IR 3.9/1000 pyrs).
Compared with the weighted RA cohort, disease
activity improvement was similar; malignancy rates
were lower and uveitis rates much higher. While crude
IR were similar, JIA patients had a lower risk of serious
infection (HR 0.5 (95% CI 0.3 to 0.9)).
Conclusions: This is the largest study to describe
disease activity and safety outcomes in adults with JIA
receiving TNFi. Disease activity improved after 1 year in
all disease patterns, suggesting TNFi is an effective
therapy in this population.
BACKGROUND
Juvenile idiopathic arthritis (JIA) is the most
common chronic inflammatory musculoskel-
etal disease of childhood,1 and the manage-
ment of JIA in children has evolved markedly
over the past decade, to include a more
aggressive approach with the goal of early
remission.2 3 In the UK, the current evidence
base (including clinical trials and observa-
tional data) has enabled the development of
treatment guidelines for children with JIA.4
In particular, first-line treatment with metho-
trexate, including a trial of subcutaneous
methotrexate, is recommended for children
with more severe forms of arthritis with the
addition of tumour necrosis factor inhibitors
(TNFi) for non-responders or those who are
intolerant.
JIA is not confined to childhood, and
research (albeit much from the prebiological
era) suggests at least a third of patients will
continue to have active disease in adult-
hood.5–10 Increasingly, children are entering
adulthood already receiving TNFi started in
childhood, and the limited evidence base
supports the ongoing benefits of this
therapy.11 12 In addition, however, there is a
Key messages
What is already known about this subject?
▸ Tumour necrosis factor inhibitors (TNFi) have
been shown to be an effective treatment for chil-
dren with juvenile idiopathic arthritis ( JIA) when
started in childhood.
▸ Little is known about their risks and benefits
when used for JIA for the first time in
adulthood.
What does this study add?
▸ This study shows that TNFi are an effective
therapeutic option for adults with JIA, with a
safety profile similar to that seen in rheumatoid
arthritis.
How might this impact on clinical practice?
▸ For adults with persistent or recurrent symptoms
of JIA in adulthood, introducing a TNFi at this
point can result in improvements across a range
of disease manifestations.
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cohort of patients with JIA who may require a biologic
for the first time in adulthood. For some, this will repre-
sent persistently active disease, with a proportion having
been diagnosed in later adolescence. Others may have
become lost to follow-up in late adolescence or during
transition, representing later to adult services. A third
group may represent patients who may have initially
achieved remission during childhood and then flare
again in adulthood. Finally, for many older adults with
JIA, TNFi was not an option in childhood, having only
been licensed in Europe in 2000.13 As opposed to the
effects of TNFi in adults with rheumatoid arthritis (RA),
for which effectiveness and safety outcomes are well
described,14 the medical management of adults with JIA
is not well defined, and the evidence base to support
decision-making is scarce. Factors such as very long
disease duration and an increasing number of
comorbidities may result in different response patterns
and safety profiles compared with both those seen in
younger children as well as those seen in RA.15–18
To date, only one analysis has examined treatment
response and short-term drug survival in 225 adults with
JIA (155 with known International League Against
Rheumatism19 (ILAR) subtype). This study,20 using data
from the British Society for Rheumatology Biologics
Register in Rheumatoid Arthritis (BSRBR-RA) found
that a majority of patients did experience improvement
in disease activity and physical function after the start of
TNFi therapy. Although this preliminary report was
encouraging, it was undertaken on a very small selection
of patients restrained by an attempt to classify patients
strictly according to ILAR subtype.
This analysis aims to (1) analyse outcomes, including
changes in disease activity and short-term to medium-
term safety outcomes in adults with JIA starting TNFi
therapy for the first time, (2) compare outcomes across
JIA disease patterns and (3) compare outcomes with
those observed in adults starting TNFi therapy for RA.
METHODS
This analysis included patients from BSRBR-RA, a
national cohort study established in 2001, to investigate
the long-term safety of biologics in adults with rheumatic
conditions.21 Although primarily a study of RA, patients
with diagnoses of ankylosing spondylitis (AS), psoriatic
arthritis (PsA) and other rheumatic diseases, including
JIA, have also been recruited. Ethical approval for the
BSRBR-RA was granted by the North West Multi-Centre
Research Ethics Committee in December 2000. All
patients provided written informed consent.
At the start of TNFi therapy, patient demographics
and disease activity measures are collected by a rheuma-
tology nurse including age, gender, diagnosis, year of
disease onset, past and current antirheumatic therapies,
the 28-joint Disease Activity Score (DAS28) and its indi-
vidual components,22 Medical Outcomes Study 36-item
Short Form Health Survey (SF-36),23 and Health
Assessment Questionnaire (HAQ). JIA-specific measures
such as active and limited joint count are not recorded.
Comorbidities are identified from a tick-list (see table 1
for details). Follow-up data are collected from the
medical record, 6-monthly for 3 years, then annually
thereafter and include disease activity, changes to anti-
rheumatic therapy including reasons and occurrence of
adverse events. HAQ and SF-36 were collected directly
Table 1 Characteristics of 443 adult patients with JIA at
point of starting their first TNFi
All JIA patients
Median (IQR) or
Number (%)
Gender, female 331 (75%)
Age at treatment start, years 33 (24–41)
Age at disease onset, years 13 (9–15)
Disease duration, years 22 (13–31)
Ethnicity; white 338 (95%) N=356
On methotrexate 257 (58%)
On steroids 173 (39%)
Disease pattern
Systemic onset 12 (3%)
Oligoarticular pattern 7 (2%)
Polyarticular pattern 327 (73%)*
Enthesitis-related arthritis 53 (12%)
Psoriatic arthritis 44 (10%)
TNFi at registration
Etanercept 199 (45%)
Infliximab 137 (31%)
Adalimumab 101 (23%)
Certolizumab 6 (1%)
Disease activity
28 tender joint count 14 (8–20) N=401
28 swollen joint count 10 (5–15) N=402
Patient global assessment
(100 mm VAS)
75 (65–85) N=405
ESR, mm/hour 35 (19–56) N=402
CRP, mg/L 30 (10–52) N=210
DAS28 6.2 (5.5–7.0) N=405
HAQ (0–3) 1.9 (1.5–2.4) N=403
Total comorbidities† N=423
None 227 (54%)
1 131 (31%)
≥2 65 (15%)
Smoking status N=438
Current smoker 101 (23%)
Previous smoker 79 (18%)
Never smoked 258 (59%)
*150 patients with polyarticular pattern were rheumatoid factor
positive (46% of polyarticular pattern, 33% of cohort overall).
†Comorbidities include; hypertension, angina, myocardial
infarction, stroke, epilepsy, asthma, chronic bronchitis/
emphysema, peptic ulcer, liver disease, renal disease,
tuberculosis, demyelination, diabetes, hyperthyroidism,
depression, cancer.
Presenting number (%), or median (IQR), including number with
available data (N) where applicable.
CRP, C reactive protein; DAS28, 28-joint Disease Activity Score;
ESR, erythrocyte sedimentation rate; HAQ, Health Assessment
Questionnaire; JIA, juvenile idiopathic arthritis; TNFi, tumour
necrosis factor inhibitor; VAS, visual analog scale.
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from all patients, 6-monthly for 3 years, according to the
original BSRBR protocol. All patients are flagged with
the Health and Social Care Information Centre
(HSCIC) for occurrence of death and malignancy,
which were reported directly to the BSRBR-RA.
Previous work in this cohort has identified that most
patients with childhood onset arthritis were not classi-
fied as having JIA, but rather given an alternative ‘adult’
diagnosis (eg, RA, AS, PsA).20 Therefore, based on year
of birth and year of symptom onset, patients with an esti-
mated disease onset age of <16 years were identified
from the cohort. Patients with a non-arthritis diagnosis
were excluded (eg, vasculitis) and the others grouped
according to disease pattern, using information available
in their study file: oligoarticular course (BSRBR-RA diag-
nosis of pauciarticular or oligoarticular JIA, or <5
swollen or tender joints ever recorded in the database),
PsA (BSRBR-RA diagnosis of PsA or systemic psoriasis
ever recorded), enthesitis-related arthritis (ERA)
(BSRBR-RA diagnosis of AS or ERA), systemic arthritis
(BRSBR-RA diagnosis of systemic JIA or Still’s disease)
and polyarticular course (BSRBR-RA diagnosis of polyar-
ticular JIA (extended, rheumatoid factor negative or
positive polyarthrits), or ≥5 swollen or tender joints ever
recorded in the database). For adults with systemic arth-
ritis or oligoarticular-course JIA, further information was
obtained from their rheumatologist confirming their
disease pattern, as the BSRBR-RA does not record sys-
temic features and only records a 28-joint count.
The primary analysis included all patients with JIA
starting their first TNFi therapy within 6 months of regis-
tration with the BSRBR-RA. Disease activity data at 1 year
were analysed and outcomes included the absolute
change from baseline (treatment start) in DAS28,
HAQ24 and SF-36; the proportion of patients achieving
the European League Against Rheumatism (EULAR)
response25 and EULAR remission (DAS28<2.6) and the
proportion of patients achieving a minimally clinical
important difference (MCID) in HAQ of >0.22 units26
are presented. Kaplan-Meier curves were generated for
survival on first TNFi therapy.
Rates of key serious adverse events (SAE) (infections,
cardiovascular, uveitis, malignancies and deaths), with
serious defined to include death, life threatening, hopsi-
talisation or disability, were determined. Only malignan-
cies reported via the HSCIC or confirmed to the
BSRBR-RA with histology were included. For deaths and
malignancies, the exposure window began with the first
dose of TNFi and continued until the event or 25 June
2014 (date of data lock for this analysis), regardless of
changes to therapies (ie, an ever-exposed model). For
other SAEs, the exposure window began with the first
dose of TNFi and continued until the event, last
returned follow-up form, or date of first missed dose of
TNFi plus 90 days, whichever came first (ie, on-drug ana-
lysis). Crude incidence rates per 1000 person-years
(pyrs) were calculated. Standardised incidence ratios
(SIR) for malignancies and standardised mortality ratio
(SMR) were calculated using UK population age and
gender cancer and mortality rates provided by the
Office for National Statistics (ONS).27
A cohort of 7877 patients in the BSRBR-RA with a
physician diagnosis of RA and symptom onset ≥17 years
old with the same age distribution as the JIA cohort at
point of starting their first TNFi therapy was also identi-
fied and their outcomes were compared, using the same
methods as the primary analysis, with adults with polyar-
ticular JIA using an age-weighted and gender-weighted
analysis. The RA patients were given a weight based on
the ratio of JIA to RA patients for that age and gender
group. For example, there were 14 female JIA patients
aged 21 years old at registration, compared with 11 RA
patients. Therefore, each of those 11 RA patients was
given the weight of 14/11 (a weight >1). For females
aged 48 years at registration, there were 3 JIA patients
compared with 204 RA patients. Therefore, each of
those 204 RA patients was given the weight of 3/204 (a
weight <1). All JIA patients were given the weight of
1. As there were no male RA patients aged <20 years old
and no female RA patients <18, males with JIA <20 years
(n=6) and females with JIA <18 years (n=11) were
weighted against RA patients aged 18 and 20, respect-
ively. Baseline and effectiveness data were compared
using linear and logistic regressions assuming analytic
weights. Safety data were compared using Cox propor-
tional hazards model assuming importance weights.
The analyses included all data available up to 30
November 2014 and were performed using Stata V.13
(StataCorp, College Station, Texas, USA).
RESULTS
In total, 553 patients with JIA were identified, of whom
443 were starting their first TNFi therapy; 75% were
female, median age at drug start was 33 years (IQR
24–41) and the majority had polyarticular-course JIA
(74%) (table 1). Only 92 (21%) were listed as having
JIA within the BSRBR-RA data set, the remainder were
listed as having an adult diagnosis. In total, 46% of
patients reported at least one comorbidity, with depres-
sion (19%) and hypertension (17%) the most common.
Four patients reported a remote prior malignancy.
After 1 year of starting TNFi therapy, median DAS28
improved from 6.2 (IQR 5.5–7.0) to 3.8 (IQR 2.6–5.0;
p<0.0001), with 33% having a good EULAR response,
and 49% a moderate response (table 2). A total of 27%
of patients were classified as in DAS28 remission
(DAS28<2.6). Median HAQ improved from 1.9 (IQR
1.5–2.4) to 1.5 (IQR 0.9–2.1; p<0.0001) with 66% of
patients achieving a MCID in HAQ. Improvements were
seen across all disease patterns, although patient
numbers in some groups were too small to assess
significance.
For the whole JIA cohort, SF-36 outcomes improved
over 1 year from start of treatment; mean (SD) physical
component score increased from 17.4 (9.4) to 27.4
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Table 2 Effectiveness outcomes in 443 adults with JIA starting first TNFi, by disease pattern category
All
(N=443)
Polyarticular
(N=327)
Oligoarticular
(N=7)
Systemic
(N=12)
Enthesitis-related
(N=53)
Psoriatic
(N=44)
DAS28
Baseline 6.2 (5.5–7.0)
N=405
6.3 (5.6–7.0)
N=322
3.9 (3.2–5.1)
N=7
6.3 (5.8–7.1)
N=12
5.9 (4.1–6.7)
N=23
6.3 (5.5–6.9)
N=41
1 year 3.8 (2.6–5.0)
N=309
3.9 (2.8–5.0)
N=252
3.4 (2.7–3.4)
N=4
5.1 (4.2–5.8)
N=7
2.2 (1.7–4.4)
N=17
3.4 (2.4–4.3)
N=29
Change in DAS28 at 1 year −2.4 (−3.4 to −1.3)*
N=297
−2.4 (−3.4 to −1.3)*
N=248
−1.1 (−2.6 to −0.2)
N=4
−1.6 (−3.4 to −1.1)*
N=7
−2.3 (−3.8 to −1.7)*
N=10
−2.8 (−3.5 to −1.6)*
N=28
EULAR response (%) at 1 year N=297 N=248 N=4 N=7 N=10 N=28
No response 53 (18) 46 (19) 2 (50) 1 (14) 1 (10) 3 (11)
Moderate 147 (49) 125 (50) 1 (25) 5 (71) 4 (40) 12 (43)
Good 97 (33) 77 (31) 1 (25) 1 (14) 5 (50) 13 (46)
DAS28 remission (%) at 1 year 83 (27)
N=309
59 (23)
N=252
1 (25)
N=4
1 (14)
N=7
11 (65)
N=17
11 (38)
N=29
HAQ
Baseline 1.9 (1.5–3.4)
N=403
2.0 (1.6–2.4)
N=314
1.9 (1.0–2.3)
N=6
2.1 (1.9–2.6)
N=11
1.7 (0.8–2.0)
N=32
1.9 (1.4–2.3)
N=40
1 year 1.5 (1.9–2.1)
N=260
1.6 (1.0–2.1)
N=200
1.4 (0.4–1.5)
N=3
2.1 (1.6–2.3)
N=5
1.0 (0.1–1.4)
N=24
1.6 (1.1–1.9)
N=28
Change in HAQ at 1 year −0.4 (−0.8 to 0.0)*
N=242
−0.4 (−0.8 to 0.0)*
N=196
−0.6 (−0.8 to −0.5)*
N=3
−0.3 (−0.4 to −0.1)
N=5
−0.5 (−0.8 to −0.1)*
N=14
−0.5 (0.8 to −0.1)*
N=24
HAQ MCID (%) at 1 year 159 (66)
N=242
126 (64)
N=196
3 (100)
N=3
3 (60)
N=5
10 (71)
N=14
17 (71)
N=24
Presenting median (IQR), including number with available data (N) where applicable.
DAS28, 28-joint Disease Activity Score; EULAR, European League Against Rheumatism; HAQ, Health Assessment Questionnaire; JIA, juvenile idiopathic arthritis; MCID, minimal clinical
important difference; TNFi, tumour necrosis factor inhibitor.
*p<0.05.
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(12.3), and mental component score increased from
43.4 (11.1) to 49.7 (10.9) (figure 1). At 3.5 years of
follow-up, 50% of patients with JIA were still on first
TNFi (figure 2).
Of the 443 patients with JIA starting a first TNFi, there
was a mean (SD) available follow-up time of 10.0 (2.5)
years per person (table 3). Total exposure time on TNFi
was 2799 pyrs. There were 58 first serious infections on
TNFi, incidence rate (IR) 22.3 (95% CI 17.2 to 28.8)/
1000 pyrs, including 18 respiratory tract infections, 11
skin and soft tissue infections, 9 septic arthritis, 9 gastro-
intestinal, abdominal or reproductive infections, 6
urinary tract infections, 1 tuberculosis, 1 varicella and 3
reports of sepsis. There were four serious cardiovascular
events including three arrhythmias, IR 1.4 (95% CI 0.5
to 3.8)/1000 pyrs. There were 11 reports of serious
uveitis (6 on etanercept, 4 on infliximab and 1 on adali-
mumab), IR 4.0 (95% CI 2.2 to 7.3)/1000 pyrs. There
were 16 first malignancies including 5 breast cancers, 5
carcinoma in situ of the cervix, 2 melanoma, 1
non-Hodgkin’s Lymphoma, 1 non-melanoma skin
cancer, 1 squamous cell carcinoma of the lung and 1
carcinoid tumour of the appendix (none of which had
reported cancer prior to starting TNFi). The malignancy
IR (ever exposed) was 3.7/1000 pyrs, and the SIR com-
pared with the general population was 1.4 (95% CI 0.9
to 2.3). There were 21 deaths, mortality IR was 5.0/1000
pyrs and the SMR 2.5 (95% CI 1.7 to 3.9).
Compared with patients with RA, the 327 adults with
polyarticular-course JIA were similar with respect to base-
line characteristics, with the exception of longer disease
duration ( JIA 22 years vs RA 5 years) (table 4). At 1 year,
similar improvements were seen in DAS28, HAQ and
SF-36. Rates of malignancy in the JIA cohort were lower
(4.3 vs 5.5/1000 pyrs) and rates of uveitis were higher
(3.7 vs 0.7/1000 pyrs) compared with the RA cohort
(table 5). While crude rates of serious infection were
similar (23.0 and 24.6/1000 pyrs), the patients with JIA
had reduced risk (adjusted HR 0.5 (95% CI 0.3 to 0.9)).
Both cohorts had raised SIRs ( JIA 1.6 and RA 1.9) and
SMRs ( JIA 2.2 and RA 3.0).
DISCUSSION
This analysis presents the largest observational study to
date of patients with JIA starting an TNFi for the first
Figure 1 SF-36 summary and component scores in 443
adults with JIA at point of starting their first TNFi therapy and
after 1 year. JIA, juvenile idiopathic arthritis; TNFi, tumour
necrosis factor inhibitor; SF-36, 36-item Short Form Health
Survey.
Figure 2 Kaplan-Meier survival estimate of time on first TNFi
up to 10 years in 443 adults with JIA. JIA, juvenile idiopathic
arthritis; TNFi, tumour necrosis factor inhibitor.
Table 3 Serious adverse events, malignancies and
death, including crude incidence rates, SIRs and SMRs, in
all adults with JIA starting first TNFi therapy
All JIA
Total follow-up available, years 4422
Mean (SD) follow-up per person,
years
10.0 (2.5)
Total exposure time on TNFi, years 2799
Mean (SD) exposure time on TNFi
per person, years
6.4 (3.4)
Serious infections 58
Rate (95% CI)/1000 pyrs 22.3 (17.2 to 28.8)
Serious cardiovascular events 4
Rate (95% CI)/1000 pyrs 1.4 (0.5 to 3.8)
Uveitis 11
Rate (95% CI)/1000 pyrs 4.0 (2.2 to 7.3)
Malignancies 16
Rate (95% CI)/1000 pyrs 3.7 (2.3 to 6.0)
SIR 1.4 (0.9 to 2.3)
Deaths 21*
Rate (95% CI)/1000 pyrs 5.0 (3.2 to 7.6)
SMR 2.5 (1.7 to 3.9)
Death certificates were available in 20 of 21 deaths. The
underlying causes of death were as follows: infection (4),
cardiovascular disease (5: ischaemic heart disease (2), aortic
stenosis (1), dilated cardiomyopathy (1), hypertensive
encephalopathy (1)); end stage renal disease (1); peptic ulcer
disease (1); lung cancer (1); underlying rheumatic disease (8: JIA
(1); RA (5); PsA (1), AS (1)).
AS, ankylosing spondylitis; JIA, juvenile idiopathic arthritis; PsA,
psoriatic arthritis; pyrs, person-years; RA, rheumatoid arthritis;
SIR, standardised incidence ratio; SMR, standardised mortality
ratio; TNFi, tumour necrosis factor inhibitor.
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time in adulthood. Overall, a significant improvement in
disease activity was observed over the first year of
therapy with a similar short-term to medium-term safety
profile to that seen in an age-weighted and gender-
weighted cohort of patients with RA.
There is a paucity of evidence supporting the effect-
iveness of TNFi started for the first time in adults with
JIA. Many of these patients will have long-standing
disease so may have accrued significant joint damage. In
this study, despite the long disease duration, disease
activity improved after 1 year of TNFi therapy; 27%
patients achieved remission, as defined using the
DAS28, and 33% achieved a good response. This is
much higher than that reported previously in a
UK-based RA cohort, with rates of 9% and 18%,
respectively,28 although similar to the rates seen in the
weighted comparison with RA included in this analysis.
Younger age has been identified as a univariable pre-
dictor of remission and EULAR response in RA.28
Similar favourable responses were seen in HAQ and
SF-36 scores, although the scores were not as high as
those seen previously in an unselected cohort of adults
with JIA,5 indicating the severe nature of disease in the
patients included in this study.
One limitation in our assessment of disease activity
was the necessary use of the DAS28, which has been vali-
dated in RA and PsA29 but not in JIA. Therefore,
although the scores did improve following treatment,
there will be aspects of JIA not captured, including
spinal pain, enthesitis or systemic features of disease.
Table 4 Patient characteristics and disease activity measures at baseline and 1 year of 327 polyarticular JIA patients and a
weighted RA cohort starting first TNFi
Median (IQR) or % Polyarticular JIA RA (weighted analysis)
p Value ( JIA
compared with RA)
Gender, female 85% 85% 1.000
Age at treatment start, years 32 (24–42) 32 (24–42) 0.928
Age at disease onset, years 13 (8–15) 25 (20–34) 0.001
Disease duration, years 22 (14–32) 5 (2–10) 0.001
Ethnicity; white 95% 93% 0.215
On methotrexate 57% 67% 0.005
On steroids 42% 42% 0.956
RF positive 46% 60% 0.001
TNFi at registration (%) 0.002
Etanercept 42 34
Infliximab 29 26
Adalimumab 27 32
Certolizumab 2 7
Total comorbidities* (%) 0.377
None 56 60
1 30 27
≥2 14 13
Smoking status (%) 0.397
Current smoker 22 22
Previous smoker 19 23
Never smoked 59 55
DAS28
Baseline 6.3 (5.6–7.0) 6.3 (5.6–6.9) 0.992
1 year 3.9 (2.8–5.0) 3.8 (2.5–5.1) 0.991
Change in DAS28 at 1 year −2.4 (−3.4 to −1.3) −2.6 (−3.6 to −1.2) 0.589
EULAR response (%) at 1 year 0.359
No response 19 20
Moderate 50 43
Good 31 37
DAS28 remission (%) at 1 year 23 26 0.539
HAQ
Baseline 2.0 (1.6–2.4) 1.9 (1.4–2.3) 0.005
1 year 1.6 (1.0–2.1) 1.4 (0.8–2.0) 0.033
Change in HAQ at 1 year −0.4 (−0.8 to −0.1) −0.5 (−0.8 to −0.1) 0.523
HAQ MCID (%) at 1 year 64 66 0.775
*Comorbidities include; hypertension, angina, myocardial infarction, stroke, epilepsy, asthma, chronic bronchitis/emphysema, peptic ulcer, liver
disease, renal disease, tuberculosis, demyelination, diabetes, hyperthyroidism, depression, cancer.
DAS28, 28-joint Disease Activity Score; EULAR, European League Against Rheumatism; HAQ, Health Assessment Questionnaire; JIA,
Juvenile Idiopathic Arthritis; MCID, Minimally Clinical Important Difference; RA, Rheumatoid Arthritis; RF, Rheumatoid factor; TNFi, tumour
necrosis factor inhibitor.
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It is also not known whether the proposed cut-off of
DAS28 remission in RA equates to remission in JIA.
This study is one of the first to report SAE rates
among adults with JIA receiving TNFi. The observed
rate of serious infections, the most common SAE, was
similar to that reported from the German JuMBO regis-
ter,11 a cohort of adults with JIA who started biological
therapies as children. The absolute risk of other SAEs
was low. As we did not have access to an untreated
cohort of adults with JIA receiving non-biological therap-
ies, the rates of SAEs was compared with patients with
RA using a weighted analysis to account for the different
age and gender structures of the two populations. The
short-term to medium-term safety profile of TNFi com-
pared with standard therapy in RA is well characterised.
The incident rate for serious infections was similar in
the JIA and RA cohorts but much lower when compared
with previous reports in RA.30 This would be expected
as age is a reported independent predictor of serious
infection. Investigation of risk associated with individual
TNFi drugs was not possible due to small sample size.
Malignancy rates and SIRs have not previously been
reported in adults with JIA. The rates are expectedly
higher than those reported in children with JIA, given
the higher background rate in adults. Similar to some
studies in children, we did observe a possible increase in
malignancy compared with the general population,31–33
although the numbers of any individual malignancy
were too small to assess rates of specific cancers. In RA,
it has been shown that the risk of lymphoma is
increased, which has also been linked strongly to
chronic inflammation.34 No study to date has looked
into rates of malignancies by JIA disease pattern. The
current study was able to estimate similar rates for the
polyarticular disease course; however, numbers were too
small to investigate in the other disease patterns.
Without an untreated adult JIA cohort, it is not possible
to comment on any association between TNFi and the
risk of malignancy, although overall, in RA no increase
in cancer has been found following TNFi therapy.35
Mortality rates were also increased compared with the
general population, both overall and among those with
polyarticular course disease. Studies of mortality in JIA,
primarily in children, have been conflicting with some
reporting an increase36 37 and others reporting no dif-
ference.38 In part, this may relate to the challenges in
studying a heterogenous disease such as JIA. The
patients in this study had severe, longstanding disease
requiring TNFi therapy and as such are likely to have a
different outcome compared with patients with oligoar-
thritis who achieve remission in childhood.
Although most SAE rates were similar to or lower than
that observed in RA, we did observe an increase in the
occurrence of uveitis among patients with JIA, which is a
Table 5 Rates and relative risk of serious adverse events in adults with polyarticular JIA and RA
Polyarticular JIA RA (weighted analysis)
Total follow-up available (pyrs) 3228 2761
Mean (SD) follow-up per person (years) 9.9 (2.5) 8.4 (3.6)
Total exposure time to TNFi (years) 1959 1609
Mean (SD) exposure time to TNFi per person (years) 6.1 (3.5) 5.3 (3.5)
Serious infections 42 37
Rate (95% CI)/1000 pyrs 23.0 (17.0 to 31.9) 24.6 (16.9 to 37.3)
HR (95% CI) 1.0 (0.6 to 1.5) (base)
Disease duration-adjusted HR (95% CI) 0.5 (0.3 to 0.9) (base)
Serious cardiovascular events 3 5
Rate (95% CI)/1000 pyrs 1.5 (0.5 to 7.6) 3.0 (2.0 to 4.7)
HR (95% CI) 0.5 (0.1 to 2.2) (base)
Disease duration-adjusted HR (95% CI) 0.3 (0.04 to 1.8) (base)
Uveitis 7 1
Rate (95% CI)/1000 pyrs 3.7 (1.8 to 8.8) 0.7 (0.2 to 4.1)
HR (95% CI) 5.1 (0.7 to 36.2) (base)
Disease duration-adjusted HR (95% CI) 4.7 (0.5 to 40.1) (base)
Malignancies 13 14
Rate (95% CI)/1000 pyrs 4.3 (2.5 to 7.9) 5.5 (3.9 to 8.0)
HR (95% CI) 0.8 (0.4 to 1.6) (base)
Disease duration-adjusted HR (95% CI) 0.4 (0.1 to 1.1) (base)
SIR 1.6 (0.9 to 2.9) 1.9 (1.4 to 2.8)
Deaths 14 16
Rate (95% CI)/1000 pyrs 4.5 (2.7 to 8.1) 6.1 (2.7 to 16.9)
HR (95% CI) 0.7 (0.4 to 1.5) (base)
Disease duration-adjusted HR (95% CI) 0.2 (0.1 to 0.6) (base)
SMR 2.2 (1.3 to 4.0) 3.0 (1.3 to 8.2)
HR, hazard ratio; JIA, juvenile idiopathic arthritis; pyrs, person-years; RA, rheumatoid arthritis; SIR, standardised incidence ratio; SMR,
standardised mortality ratio; TNFi, tumour necrosis factor inhibitor.
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recognised comorbidity of the disease.39 Of these 11
cases, 7 had known inflammatory eye disease at the start
of therapy, although specific details or diagnosis are not
captured by the BSRBR-RA. It was unfortunately not pos-
sible to tell if the reports of uveitis following therapy
were new occurrences or flare of prior disease.
This is the largest study in a cohort of adults with JIA
focusing on the effectiveness and safety of TNFi but
does have some limitations. The majority of our patients
had polyarticular course disease and therefore, our
results will be less applicable to other JIA subtypes. The
predominance of polyarticular course likely relates to a
number of factors, including the design of the
BSRBR-RA, which had a primary focus of recruiting
patients with RA. Also, during the earlier years of
recruitment, TNFi did not yet have a license or approval
for use in the UK for conditions other than RA or chil-
dren with polyarticular JIA. Indeed, many adults with
JIA may have been ‘relabelled’ as having RA specifically
for the purpose of gaining access to TNFi. The use of
RA and other adult treatment pathways is also high-
lighted by the choice of infliximab and certolizumab in
this population, two therapies which are not licensed in
Europe for JIA. We did not have access to a comparable
cohort of adults with JIA who had not received a bio-
logic and therefore we compared outcomes with those
seen in RA, where the experience with TNFi has been
better characterised, including in comparison to
untreated patients.30 35 40 These data cannot be used to
address questions of whether TNFi increases the risk of
adverse events compared with non-biological therapies
in this population. Overall, it has highlighted a strong
need for studies investigating long-term outcomes of
adults with JIA, potentially starting from disease onset,
and to encourage data collection into adulthood.
Conclusions
The treatment pathway for adults with JIA is poorly
defined, with most adults either following JIA treatment
guidelines designed for children or being reclassified as
adults (eg, RA, AS or PsA) to inform ongoing care. Our
study has shown that for those patients with active JIA in
adulthood who are naïve to biological therapy, TNFi was
an effective choice of therapy in many patients with a
favourable safety profile, not dissimilar to that seen in
RA and provides further evidence for biological therapy
use in this population. There is an ongoing need for
consensus-derived care pathways to guide rheumatolo-
gists working with adults with JIA.
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